FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Richardson

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Phenomena

Recurrence

Physiology

Drug Resistance, Neoplasm

Anatomy

Co-author Network

Publications

TOP 3
Sergio Giralt; Kenneth C Anderson; Shelly L Carter; Ginna G Laport; Philip L McCarthy; Marcelo C Pasquini; S Vincent Rajkumar; Paul G Richardson; Edward A Stadtmauer; Mary M Horowitz
Anatomy of a successful practice-changing study: a blood and marrow transplantation clinical trials network-national cancer institute cooperative group collaboration.
Güllü Topal Görgün; Teru Hideshima; Jacob Laubach; Craig Maguire; Nikhil C Munshi; Noopur Raje; Paul G Richardson; Gregory Whitehill; Jennifer L Anderson; Kenneth C Anderson
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Paul G Richardson; Robert Schlossman; David Siegel; Daniel Sullivan; Sandra Wear; Mohamad H Zaki; Melissa Alsina; Palka Anand; Rachid Baz; Elizabeth Bilotti; Min Chen; Deborah Doss; Irene M Ghobrial; Christian Jacques; Susan L Kelley; Gail Larkins; Jacob Laubach; Nora Loughney; Laura McBride; Nikhil C Munshi; Lisa Nardelli; Kenneth C Anderson
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Richardson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sergio Giralt; Kenneth C Anderson; Shelly L Carter; Ginna G Laport; Philip L McCarthy; Marcelo C Pasquini; S Vincent Rajkumar; Paul G Richardson; Edward A Stadtmauer; Mary M Horowitz
Anatomy of a successful practice-changing study: a blood and marrow transplantation clinical trials network-national cancer institute cooperative group collaboration.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(6):858-9.
2013: Güllü Topal Görgün; Teru Hideshima; Jacob Laubach; Craig Maguire; Nikhil C Munshi; Noopur Raje; Paul G Richardson; Gregory Whitehill; Jennifer L Anderson; Kenneth C Anderson
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Blood 2013;121(15):2975-87.
2013: Paul G Richardson; Robert Schlossman; David Siegel; Daniel Sullivan; Sandra Wear; Mohamad H Zaki; Melissa Alsina; Palka Anand; Rachid Baz; Elizabeth Bilotti; Min Chen; Deborah Doss; Irene M Ghobrial; Christian Jacques; Susan L Kelley; Gail Larkins; Jacob Laubach; Nora Loughney; Laura McBride; Nikhil C Munshi; Lisa Nardelli; Kenneth C Anderson
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Blood 2013;121(11):1961-7.
2013: Irene M Ghobrial; Janet Kunsman; Farzana Masood; Kenneth C Anderson; Feda Azab; Ranjit Banwait; Erica N Boswell; Federico Campigotto; Stacey Chuma; Amanda Donovan; Timothy J Murphy; Paul G Richardson; Scott Rodig; Diane Warren; Edie Weller; Jeffrey Matous
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
Blood 2013;121(8):1296-303.
2013: Paul G Richardson; Marco Sardella; Enric Carreras; Selim Corbacioglu; Sergio Giralt; Vincent T Ho; Ernst Holler; Margaret Hoyle; Nancy A Kernan; Leslie Lehmann; Michelle Maglio; Craig Maguire; Dietger Niederwieser; Robert Soiffer
Drug safety evaluation of defibrotide.
Expert opinion on drug safety 2013;12(1):123-36.
2013: Paul G Richardson; Joseph H Antin; Corey Cutler; B Glotzbecker; Vincent T Ho; Robert J Soiffer
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(1 Suppl):S88-90.
2013: Michele Cea; Marco Gobbi; Teru Hideshima; Franco Patrone; Paul G Richardson; Antonia Cagnetta; Kenneth C Anderson
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Current pharmaceutical design 2013;19(4):734-44.
2012: David I Lichter; Sagar Lonial; George Mulligan; Ruben Niesvizky; Michael D Pickard; Deborah Ricci; Paul G Richardson; Hongliang Shi; Michael Sintchak; Pieter Sonneveld; Olga Tayber; William L Trepicchio; Helgi van de Velde; Joan Bladé; Jamie Cavenagh; William Dalton; Hadi Danaee; Dixie Esseltine; Thierry Façon; Melissa Alsina; Kenneth C Anderson
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Blood 2012;120(23):4513-6.
2012: Steffen Klippel; Jacob Laubach; Douglas W McMillin; Kenneth C Anderson; Jake Delmore; Jana Jakubikova; Efstathios Kastritis; Melissa Ooi; Paul G Richardson; Constantine S Mitsiades
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.
British journal of haematology 2012;159(3):340-51.
2012: Niels W C J van de Donk; Kenneth C Anderson; Henk M Lokhorst; Paul G Richardson
How I treat plasma cell leukemia.
Blood 2012;120(12):2376-89.
2012: Paul G Richardson; Nicole Stavitzski; Joseph H Antin; Sally Arai; Enric Carreras; Corey Cutler; Sergio Giralt; Vincent T Ho; Ernst Holler; Shin Mineishi; Dietger Niederwieser; Robert Soiffer
Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.
Therapeutic advances in hematology 2012;3(4):253-65.
2012: Andrzej J Jakubowiak; Malathi Kandarpa; Jonathan L Kaufman; Stephanie Kraftson; Enrique Poradosu; Paul G Richardson; Charles W Ross; Peter Sportelli; Todd Zimmerman; Lesa Gardner; Kathy Giusti; Colleen Harvey; Teru Hideshima; Melissa Alsina; Kenneth C Anderson
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
British journal of haematology 2012;158(4):472-80.
2012: Sachin S Saboo; Kenneth C Anderson; Lina Benajiba; Fiona Fennessy; Jacob Laubach; Paul G Richardson
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(20):e175-9.
2012: Michel Delforge; Ravinder Dhawan; Dixie Esseltine; Juliette Meunier; Antoine Regnault; Paul G Richardson; Don Robinson; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
European journal of haematology 2012;89(1):16-27.
2012: Naoya Mimura; Jiro Minami; Nikhil C Munshi; Hiroto Ohguchi; John B Patterson; Tuan Pham; Paul G Richardson; Loredana Santo; Yu-Tzu Tai; Victor Tam; Qingping Zeng; Martina Blumenthal; Diana Cirstea; Claire Fabre; Maureen French; Mariateresa Fulciniti; Gullu Gorgun; Mark Hokenson; Yiguo Hu; Hiroshi Ikeda; Yutaka Kawano; Nathalie L Kertesz; Tanyel Kiziltepe; Uriel M Malyankar; Kenneth C Anderson
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Blood 2012;119(24):5772-81.
2012: Selim Corbacioglu; Stephan Grupp; Nancy Kernan; Leslie Lehmann; Paul Martin; Carolyn Revta; Joel Brochstein; Paul G Richardson
Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Expert review of hematology 2012;5(3):291-302.
2012: Merav Leiba; Constantine S Mitsiades; Arnon Nagler; Mark Pines; Paul G Richardson; Yu-Tzu Tai; Teru Hideshima; Jana Jakubikova; Steffen Klippel; Adi Leiba; Kenneth C Anderson
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
British journal of haematology 2012;157(6):718-31.
2012: Andrzej J Jakubowiak; Ann Mohrbacher; Paul G Richardson; David S D Siegel; Anil K Singhal; Todd M Zimmerman; Daniel E H Afar; William Bensinger; Don M Benson; Kenneth C Anderson
Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(16):1960-5.
2012: Philip L McCarthy; Brian McClune; Jan S Moreb; Kouros Owzar; Marcelo C Pasquini; John Postiglione; Muzaffar H Qazilbash; Paul G Richardson; Cara Rosenbaum; Robert Schlossman; Michele Seiler; Thomas C Shea; Edward A Stadtmauer; Koen Van Besien; Ravi Vij; Daniel J Weisdorf; Kenneth C Anderson; Susan Barry; Asad Bashey; Elizabeth Bennett; Linda Bressler; Natalie Scott Callander; Steven M Devine; Don A Gabriel; Teresa Gentile; Sergio Giralt; Parameswaran Hari; Vera Hars; Hani Hassoun; Craig C Hofmeister; Mary M Horowitz; David D Hurd; Luis Isola; Chen Jiang; Michael Kelly; Heather Landau; Denise Levitan; Thomas Martin; Richard T Maziarz; Charles Linker
Lenalidomide after stem-cell transplantation for multiple myeloma.
The New England journal of medicine 2012;366(19):1770-81.
2012: Shaji Kumar; George Mulligan; Stephen J Noga; Natalie Callander; Jose Estevam; Ian W Flinn; Parameswaran Hari; Paul G Richardson; Robert Rifkin; Hongliang Shi; A Keith Stewart; Francesco Turturro; Iain J Webb; Jeffrey Wolf; S Vincent Rajkumar
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Blood 2012;119(19):4375-82.
2012: Paul G Richardson; Cathy Eng; Teru Hideshima; Jill Kolesar; Kenneth C Anderson
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Expert opinion on drug metabolism & toxicology 2012;8(5):623-33.
2012: Paul G Richardson; Robert L Schlossman; Diane Warren; Kathleen Colson; Deborah Doss; Irene M Ghobrial; Teru Hideshima; Jacob P Laubach; Laura Lunde; Mary McKenney; Constantine S Mitsiades; Nikhil C Munshi; Kimberly Noonan; Katherine C Redman; Kenneth C Anderson
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
European journal of haematology 2012;88(5):446-9.
2012: Douglas W McMillin; Kenneth C Anderson; Jake Delmore; Glenn Dranoff; Shohei Koyama; Jacob Laubach; Nikhil C Munshi; Joseph M Negri; Paul G Richardson; Robert L Schlossman; Matthew Vanneman; Constantine S Mitsiades
Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
Blood 2012;119(15):e131-8.
2012: Douglas W McMillin; Kenneth C Anderson; Leutz Buon; Jake E Delmore; Zachary R Hunter; Hannah M Jacobs; Andrew L Kung; Val Monrose; Paul G Richardson; Peter G Smith; Steven P Treon; Jie Yu; Constantine S Mitsiades
Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
Molecular cancer therapeutics 2012;11(4):942-51.
2012: Paul G Richardson; O Sezer; D Siegel; E Terpos; S Usmani; D Vesole; P Voorhees; P Wen; Kenneth C Anderson; H Avet-Loiseau; M Beksac; J Bladé; M Cavo; W J Chng; R Comenzo; M Delforge; M Dimopoulos; B G M Durie; H Einsele; Jean-Luc Harousseau; Sundar Jagannath; J L Jongen; J J Lahuerta; J H Lee; Sagar Lonial; M-V Mateos; A Mazumder; G Merlini; J San Miguel; P Moreau; G Morgan; N Munshi; R Niesvizky; Robert Z Orlowski; Antonio Palumbo; S V Rajkumar; Pieter Sonneveld
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Leukemia 2012;26(4):595-608.
2012: Heinz Ludwig; Maria-Victoria Mateos; Philip McCarthy; Gareth Morgan; Ruben Niesvizky; Robert Z Orlowski; Antonio Palumbo; Paul G Richardson; Jésus San Miguel; Pieter Sonneveld; Andrew Spencer; Keith A Stewart; Anders Waage; Pierre Wijermans; Kenneth C Andersen; Michel Attal; Bart Barlogie; Meral Beksac; P Leif Bergsagel; Michele Cavo; Brian G M Durie; Hermann Einsele; Thierry Facon; Axel Hinke; Cyrille Hulin; Ola Landgren; Henk Lokhorst
IMWG consensus on maintenance therapy in multiple myeloma.
Blood 2012;119(13):3003-15.
2012: Meletios A Dimopoulos; Nancy Brandenburg; Ruben Niesvizky; Paul G Richardson; Donna M Weber; Zhinuan Yu; Gareth J Morgan
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.
Blood 2012;119(12):2764-7.
2012: Anuj Mahindra; Nikhil Munshi; Noopur Raje; Paul G Richardson; Jacob Laubach; Kenneth C Anderson
Latest advances and current challenges in the treatment of multiple myeloma.
Nature reviews. Clinical oncology 2012;9(3):135-43.
2012: Mahmoud R Gaballa; Irene M Ghobrial; Jacob P Laubach; Constantine S Mitsiades; Nikhil Munshi; Kimberly Noonan; Katherine Redman; Kenneth C Anderson; Robert L Schlossman; Paul G Richardson
Management of myeloma-associated renal dysfunction in the era of novel therapies.
Expert review of hematology 2012;5(1):51-66; quiz 67-8.
2012: Niels Wcj van de Donk; Güllü Görgün; Richard Wj Groen; Teru Hideshima; Jana Jakubikova; Jacob Laubach; Henk M Lokhorst; Constantine S Mitsiades; Inger S Nijhof; Reinier A Raymakers; Paul G Richardson; Kenneth C Anderson
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
Cancer management and research 2012;4():253-68.
2012: Paul G Richardson; Irene M Ghobrial; Robert L Schlossman; Jacob P Laubach; Noopur Raje; Constantine S Mitsiades; Jacalyn Rosenblatt; Nikhil Munshi; Anuj Mahindra; Kenneth C Anderson
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
European journal of haematology 2012;88(1):1-7.
2012: Shaji Kumar; J J Lahuerta; J H Lee; X LeLeu; J S Miguel; P Moreau; G Morgan; Robert Z Orlowski; Antonio Palumbo; S Vincent Rajkumar; Paul G Richardson; O Sezer; D Siegel; Pieter Sonneveld; Joan Bladé; John Crowley; B G M Durie; J Feather; H Goldschmidt; Jeffrey Haessler; Antje Hoering; C Hulin; Sundar Jagannath; S K Klein
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Leukemia 2012;26(1):149-57.
2012: C L Echart; J Fareed; Antonio Palumbo; Paul G Richardson; S Somaini; M Distaso; M Iacobelli
Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012;18(1):79-86.
2011: David Siegel; David H Vesole; Julian Adams; Kenneth C Anderson; Ivan Borello; Joi Dunbar; Jill Goddard; David Grayzel; Sundar Jagannath; Amitabha Mazumder; Constantine Mitsiades; Emmanuel Normant; Paul G Richardson
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
Leukemia & lymphoma 2011;52(12):2308-15.
2011: Paul G Richardson; Robert Schlossman; Peter Sportelli; Jeff Wolf; Jeffrey A Zonder; Jeff Allerton; Michael Bar; Kathleen Colson; John Densmore; Lesa Gardner; Irene M Ghobrial; Teru Hideshima; David Irwin; Andrzej J Jakubowiak; Amrita Krishnan; Jacob Laubach; Sagar Lonial; Tom Martin; Nikhil Munshi; Enrique Poradosu; Noopur Raje; Kenneth C Anderson
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):4243-9.
2011: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
Molecular cancer therapeutics 2011;10(11):2034-42.
2011: Mark van Duin; Bronno van der Holt; Annemiek Broyl; Yvonne de Knegt; Hartmut Goldschmidt; Wim C J Hop; Debora Joseph-Pietras; George Mulligan; Rachel Neuwirth; Paul G Richardson; Surinder S Sahota; Pieter Sonneveld
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
Haematologica 2011;96(11):1662-9.
2011: Jacob P Laubach; Marlise R Luskin; Anuj Mahindra; Constantine S Mitsiades; Nikhil C Munshi; Noopur Raje; Kenneth C Anderson; David Avigan; Irene M Ghobrial; Jacalyn Rosenblatt; Robert L Schlossman; Paul G Richardson
Management of relapsed and relapsed/refractory multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(10):1209-16.
2011: Jake E Delmore; Irene M Ghobrial; Timothy Gilpatrick; William C Hahn; Timothy P Heffernan; Ghayas C Issa; Hannah M Jacobs; Efstathios Kastritis; Andrew L Kung; Madeleine E Lemieux; Michael R McKeown; Ronald M Paranal; Jun Qi; Peter B Rahl; Paul G Richardson; Anna C Schinzel; Junwei Shi; Christopher R Vakoc; Richard A Young; Kenneth C Anderson; P Leif Bergsagel; James E Bradner; Marta Chesi; Constantine S Mitsiades
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Cell 2011;146(6):904-17.
2011: Ivan Spicka; M A Dimopoulos; M V Mateos; K Redman; Paul G Richardson
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation.
Immunotherapy 2011;3(9):1033-40.
2011: Dharminder Chauhan; Deborah Kuhn; Robert Z Orlowski; Noopur Raje; Paul G Richardson; Ze Tian; Bin Zhou; Kenneth C Anderson
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(16):5311-21.
2011: Jana Jakubikova; Kihyun Kim; Steffen Klippel; Merav Leiba; Douglas W McMillin; Kenneth C Anderson; Simona Blotta; David Cervi; Dana Cholujova; John F Daley; Jake Delmore; Teru Hideshima; Sabikun Nahar; Joseph Negri; Melissa Ooi; Paul G Richardson; Jan Sedlak; Constantine S Mitsiades
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Haematologica 2011;96(8):1170-9.
2011: Andrzej J Jakubowiak; Mark S Kaminski; Susan L Kelley; Jacob P Laubach; Sagar Lonial; Melissa A Mietzel; Noopur S Raje; Donna E Reece; Kenneth C Anderson; Tara Anderson; Jennifer C Barrickman; Erica L Campagnaro; Dixie Esseltine; Kent Andrew Griffith; Colleen K Harvey; Craig C Hofmeister; Robert L Schlossman; Craig L Tendler; Sandra M Wear; Todd M Zimmerman; Paul G Richardson
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood 2011;118(3):535-43.
2011: Irene M Ghobrial; Brianna N Harris; Jacob P Laubach; Nikhil C Munshi; Scott P Myrand; Nichole M Porter; Paul G Richardson; Robert L Schlossman; Peipei Shi; James E Wooldridge; Kenneth C Anderson; Durisala Desaiah; Rafat Abonour
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
American journal of hematology 2011;86(7):573-8.
2011: Michele Cavo; Meletios A Dimopoulos; Brian G M Durie; Hermann Einsele; Gösta Gahrton; Sundar Jagannath; Hans E Johnsen; Nicolaus Kroeger; Sagar Lonial; Heinz Ludwig; Philippe Moreau; Ruben Niesvizky; Robert Z Orlowski; Antonio Palumbo; S Vincent Rajkumar; Paul G Richardson; Jesus San Miguel; Orhan Sezer; Pieter Sonneveld; David H Vesole; Kenneth C Anderson; Michel Attal; William Bensinger; P Leif Bergsagel; Joan Bladé; Mario Boccadoro
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Blood 2011;117(23):6063-73.
2011: Paul G Richardson; Robert L Schlossman; Irene M Ghobrial; Jacob Laubach; Constantine S Mitsiades; Nikhil C Munshi; Kenneth C Anderson
MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
Oncology (Williston Park, N.Y.) 2011;25(7):594, 596.
2011: Paul G Richardson; Asher A Chanan-Khan; Sagar Lonial; Amrita Y Krishnan; Michael P Carroll; Melissa Alsina; Maher Albitar; David Berman; Marianne Messina; Kenneth C Anderson
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
British journal of haematology 2011;153(6):729-40.
2011: Constantine S Mitsiades; Faith E Davies; Jacob P Laubach; Douglas Joshua; Kenneth C Anderson; Jesus San Miguel; Paul G Richardson
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(14):1916-23.
2011: Jacob Laubach; Paul G Richardson; Kenneth C Anderson
Hematology: Setting the standard for newly diagnosed multiple myeloma.
Nature reviews. Clinical oncology 2011;8(5):255-6.
2011: Michel Delforge; Evangelos Terpos; Paul G Richardson; Ofer Shpilberg; Nuriet K Khuageva; Rudolf Schlag; Meletios A Dimopoulos; Martin Kropff; Ivan Spicka; Maria T Petrucci; Olga S Samoilova; Maria-Victoria Mateos; Hila Magen-Nativ; Hartmut Goldschmidt; Dixie Esseltine; Deborah S Ricci; Kevin Liu; William Deraedt; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
European journal of haematology 2011;86(5):372-84.
2011: Jana Jakubikova; Sophia Adamia; Maria Kost-Alimova; Steffen Klippel; David Cervi; John F Daley; Dana Cholujova; Sun-Young Kong; Merav Leiba; Simona Blotta; Melissa Ooi; Jake Delmore; Jacob Laubach; Paul G Richardson; Jan Sedlak; Kenneth C Anderson; Constantine S Mitsiades
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Blood 2011;117(17):4409-19.
2011: Rajesh Rajpal; Paul Dowling; Justine Meiller; Colin Clarke; William G Murphy; Robert O'Connor; Malcolm Kell; Constantine Mitsiades; Paul G Richardson; Kenneth C Anderson; Martin Clynes; Peter O'Gorman
A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
Proteomics 2011;11(8):1391-402.
2011: Sacha N Uljon; Paul G Richardson; Peter H Schur; Kenneth C Anderson; Milenko J Tanasijevic; Neal I Lindeman
Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.
Clinica chimica acta; international journal of clinical chemistry 2011;412(7-8):562-8.
2011: Sagar Lonial; Constantine S Mitsiades; Paul G Richardson
Treatment options for relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(6):1264-77.
2011: Irene M Ghobrial; Edie Weller; Ravi Vij; Nikhil C Munshi; Ranjit Banwait; Meghan Bagshaw; Robert Schlossman; Renee Leduc; Stacey Chuma; Janet Kunsman; Jacob Laubach; Andrzej J Jakubowiak; Patricia Maiso; Aldo Roccaro; Philippe Armand; Akari Dollard; Diane Warren; Brianna Harris; Tiffany Poon; Amy Sam; Scott Rodig; Kenneth C Anderson; Paul G Richardson
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
The lancet oncology 2011;12(3):263-72.
2011: Reyna Favis; Yu Sun; Helgi van de Velde; Erin Broderick; Laura Levey; Michael Meyers; George Mulligan; Jean-Luc Harousseau; Paul G Richardson; Deborah S Ricci
Genetic variation associated with bortezomib-induced peripheral neuropathy.
Pharmacogenetics and genomics 2011;21(3):121-9.
2011: Meletios-Athanassios Dimopoulos; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Tanespimycin as antitumor therapy.
Clinical lymphoma, myeloma & leukemia 2011;11(1):17-22.
2011: Jacob P Laubach; Robert Schlossman; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Expert review of hematology 2011;4(1):51-60.
2011: Douglas W McMillin; Jake Delmore; Joseph Negri; Leutz Buon; Hannah M Jacobs; Jacob Laubach; Jana Jakubikova; Melissa Ooi; Patrick Hayden; Robert Schlossman; Nikhil C Munshi; Christoph Lengauer; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
British journal of haematology 2011;152(4):420-32.
2011: Paul G Richardson; Constantine S Mitsiades; Jacob P Laubach; Sagar Lonial; Asher Chanan-Khan; Kenneth C Anderson
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
British journal of haematology 2011;152(4):367-79.
2011: Douglas W McMillin; Chandrasekhar V Miduturu; Joseph Negri; Melissa Ooi; Paul G Richardson; Kenneth C Anderson; Jake Delmore; Nathanael S Gray; Steffen Klippel; Andrew L Kung; Constantine S Mitsiades
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
PloS one 2011;6(7):e20226.
2011: Meletios A Dimopoulos; Maria-Victoria Mateos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Antonio Palumbo; Ka Lung Wu; Dixie Esseltine; Kevin Liu; William Deraedt; Andrew Cakana; Helgi Van De Velde; Jesús F San Miguel
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
European journal of haematology 2011;86(1):23-31.
2010: Paul G Richardson
A new standard of care in newly diagnosed multiple myeloma.
Lancet 2010;376(9758):2043-4.
2010: Paul G Richardson
Improving the therapeutic index in myeloma.
Blood 2010;116(23):4733-4.
2010: Meletios A Dimopoulos; Evangelos Terpos; Asher Chanan-Khan; Nelson Leung; Heinz Ludwig; Sundar Jagannath; Ruben Niesvizky; Sergio Giralt; Jean-Paul Fermand; Joan Bladé; Raymond L Comenzo; Orhan Sezer; Antonio Palumbo; Jean-Luc Harousseau; Paul G Richardson; Bart Barlogie; Kenneth C Anderson; Pieter Sonneveld; Patrizia Tosi; Michele Cavo; S Vincent Rajkumar; Brian G M Durie; Jésus San Miguel
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4976-84.
2010: Jean-Luc Harousseau; Antonio Palumbo; Paul G Richardson; Rudolf Schlag; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Alain Kentos; Michele Cavo; Anatoly Golenkov; Mieczyslaw Komarnicki; Maria-Victoria Mateos; Dixie Esseltine; Andrew Cakana; Kevin Liu; William Deraedt; Helgi van de Velde; Jesús F San Miguel
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
Blood 2010;116(19):3743-50.
2010: Paul G Richardson
Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma.
The lancet oncology 2010;11(11):1014-6.
2010: Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Giulia Perrone; Naoya Miura; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Loredana Santo; Sonia Vallet; Diana Cristea; Elisabetta Calabrese; Gullu Gorgun; Noopur S Raje; Paul G Richardson; Nikhil C Munshi; Brian J Lannutti; Kamal D Puri; Neill A Giese; Kenneth C Anderson
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
Blood 2010;116(9):1460-8.
2010: Eliot C Heher; Nelson Bahia Goes; Thomas R Spitzer; Noopur S Raje; Benjamin D Humphreys; Kenneth C Anderson; Paul G Richardson
Kidney disease associated with plasma cell dyscrasias.
Blood 2010;116(9):1397-404.
2010: Irene M Ghobrial; Wanling Xie; Swaminathan Padmanabhan; Ashraf Badros; Meghan Rourke; Renee Leduc; Stacey Chuma; Janet Kunsman; Diane Warren; Tiffany Poon; Brianna Harris; Amy Sam; Kenneth C Anderson; Paul G Richardson; Steve P Treon; Edie Weller; Jeffrey Matous
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
American journal of hematology 2010;85(9):670-4.
2010: Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David Avigan; Wanling Xie; Irene M Ghobrial; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood 2010;116(5):679-86.
2010: Paul G Richardson; Ashraf Badros; Sundar Jagannath; Stefano Tarantolo; Jeffrey L Wolf; Maher Albitar; David Berman; Marianne Messina; Kenneth C Anderson
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
British journal of haematology 2010;150(4):428-37.
2010: Paul G Richardson; Asher A Chanan-Khan; Melissa Alsina; Maher Albitar; David Berman; Marianne Messina; Constantine S Mitsiades; Kenneth C Anderson
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
British journal of haematology 2010;150(4):438-45.
2010: Corey Cutler; Haesook T Kim; Shaké Ayanian; Gary Bradwin; Carolyn Revta; Julie Aldridge; Vincent T Ho; Edwin P Alyea; John Koreth; Philippe Armand; Robert J Soiffer; Jerome Ritz; Paul G Richardson; Joseph H Antin
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(8):1180-5.
2010: Richard J Rickles; Laura T Pierce; Thomas P Giordano; Winnie F Tam; Douglas W McMillin; Jake Delmore; Jacob P Laubach; Alexis A Borisy; Paul G Richardson; Margaret S Lee
Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.
Blood 2010;116(4):593-602.
2010: Shaji Kumar; Ian W Flinn; Stephen J Noga; P Hari; R Rifkin; N Callander; M Bhandari; J L Wolf; C Gasparetto; A Krishnan; D Grosman; Jonathan D Glass; E A Sahovic; H Shi; I J Webb; Paul G Richardson; S Vincent Rajkumar
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study.
Leukemia 2010;24(7):1350-6.
2010: Rao H Prabhala; dheeraj pelluru; Mariateresa Fulciniti; Harsha K Prabhala; Puru Nanjappa; Weihua Song; Christine Pai; Samir Amin; Yu-Tzu Tai; Paul G Richardson; Irene M Ghobrial; Steve P Treon; John F Daley; Kenneth C Anderson; Jeffery L Kutok; Nikhil C Munshi
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
Blood 2010;115(26):5385-92.
2010: Paul G Richardson; Robert J Soiffer; Joseph H Antin; Hajime Uno; Zhezhen Jin; Joanne Kurtzberg; Paul L Martin; Gideon Steinbach; Karen F Murray; Georgia B Vogelsang; Allen R Chen; Amrita Krishnan; Nancy A Kernan; David Avigan; Thomas R Spitzer; Howard M Shulman; Donald N Di Salvo; Carolyn Revta; Diane Warren; Parisa Momtaz; Gary Bradwin; L J Wei; Massimo Iacobelli; George B McDonald; Eva C Guinan
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(7):1005-17.
2010: Antonio Palumbo; Alessandra Larocca; Mariella Genuardi; Katarzyna Kotwica; Francesca Gay; Davide Rossi; Giulia Benevolo; Valeria Magarotto; Federica Cavallo; Sara Bringhen; Cecilia Rus; Luciano Masini; Massimo Iacobelli; Gianluca Gaidano; Constantine Mitsiades; Kenneth C Anderson; Mario Boccadoro; Paul G Richardson
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Haematologica 2010;95(7):1144-9.
2010: María Victoria Mateos; Maria Teresa Cibeira; Paul G Richardson; Felipe Prosper; Albert Oriol; Javier de la Rubia; Juan José Lahuerta; Ramón García-Sanz; Sonia Extremera; Sergio Szyldergemajn; Claudia Corrado; Harald Singer; Constantine S Mitsiades; Kenneth C Anderson; Joan Bladé; Jesús San Miguel
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(12):3260-9.
2010: Robert A Kyle; Brian G M Durie; S Vincent Rajkumar; Ola Landgren; Joan Blade; Giampaolo Merlini; N Kröger; Hermann Einsele; David H Vesole; M Dimopoulos; Jesús San Miguel; Hervé Avet-Loiseau; R Hajek; W M Chen; Kenneth C Anderson; Heinz Ludwig; Pieter Sonneveld; Santiago Pavlovsky; Antonio Palumbo; Paul G Richardson; Bart Barlogie; Philip R Greipp; R Vescio; I Turesson; Jan Westin; Mario Boccadoro
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Leukemia 2010;24(6):1121-7.
2010: Jacob P Laubach; Paul G Richardson; Kenneth C Anderson
The evolution and impact of therapy in multiple myeloma.
Medical oncology (Northwood, London, England) 2010;27 Suppl 1():S1-6.
2010: Teru Hideshima; Constantine S Mitsiades; Hiroshi Ikeda; Dharminder Chauhan; Noopur Raje; Gullu Gorgun; Hiromasa Hideshima; Nikhil C Munshi; Paul G Richardson; Daniel R Carrasco; Kenneth C Anderson
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
Blood 2010;115(18):3772-5.
2010: Maria-Victoria Mateos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Dixie Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(13):2259-66.
2010: L Santo; S Vallet; T Hideshima; D Cirstea; H Ikeda; S Pozzi; K Patel; Y Okawa; G Gorgun; G Perrone; E Calabrese; M Yule; M Squires; M Ladetto; Mario Boccadoro; Paul G Richardson; N C Munshi; Kenneth C Anderson; N Raje
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Oncogene 2010;29(16):2325-36.
2010: Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
Nature medicine 2010;16(4):483-9.
2010: Lawrence Marks; Constance Cirrincione; Thomas J Fitzgerald; Fran Laurie; Arvin S Glicksman; James Vredenburgh; Leonard R Prosnitz; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Jinli Ma; Bercedis L Peterson; Larry Norton; Steven Seagren; I Craig Henderson; David D Hurd; William P Peters
Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082.
International journal of radiation oncology, biology, physics 2010;76(5):1305-13.
2010: Irene M Ghobrial; Morie Gertz; Betsy Laplant; John Camoriano; Suzanne Hayman; Martha Lacy; Stacey Chuma; Brianna Harris; Renee Leduc; Meghan Rourke; Stephen M Ansell; Daniel Deangelo; Angela Dispenzieri; Leif Bergsagel; Craig Reeder; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Thomas E Witzig
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(8):1408-14.
2010: Irene M Ghobrial; Fangxin Hong; Swaminathan Padmanabhan; Ashraf Badros; Meghan Rourke; Renee Leduc; Stacey Chuma; Janet Kunsman; Diane Warren; Brianna Harris; Amy Sam; Kenneth C Anderson; Paul G Richardson; Steven P Treon; Edie Weller; Jeffrey Matous
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(8):1422-8.
2010: Paul G Richardson; Jacob Laubach; Constantine Mitsiades; Robert L Schlossman; Deborah Doss; Kathleen Colson; Mary L McKenney; Kimberly Noonan; Diane L Warren; Irene M Ghobrial; Nikhil C Munshi; Kenneth C Anderson
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Oncology (Williston Park, N.Y.) 2010;24(3 Suppl 2):22-9.
2010: Paul G Richardson; Jacob P Laubach; Robert L Schlossman; Constantine Mitsiades; Kenneth C Anderson
Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8 Suppl 1():S4-S12.
2010: Rafael Fonseca; Paul G Richardson; Sergio Giralt; Sagar Lonial; S Vincent Rajkumar; A Keith Stewart; William Bensinger; George Somlo; Robert Vescio; Joseph Mikhael; Craig Reeder; Rodger Tiedemann; Guido Tricot; Robert Rifkin; John Shaughnessy; Nikhil Munshi; Noopur Raje; Irene Ghobrial; Jacob Laubach; Robert Schlossman; Steven Treon; Anuj Mahindra; David Avigan; Jacalyn Rosenblatt; Sundar Jagannath; Ruben Niesvizky; Heather Landau; Selina Chen-Kiang; David S Siegel; Todd Zimmerman; Jayesh Mehta; David Vesole; Steven Rosen; Craig Hofmeister; Martha Lacy; Angela Dispenzieri; Ivan Borrello; Suzanne R Hayman; Shaji Kumar; Frances Buadi; David Dingli; Stephen Russell; Melissa Alsina Melissa Alsina; Hugo Fernandez; Vivek Roy; Denise Pereira; Edward Stadtmauer; Ravi Vij; Andrzej Jakubowiak; Suzanne Lentzsch; Kevin Song; Suzanne Trudel; Christine Chen; Donna Reece; Douglas Stewart; Seema Singhal; Raymond Comenzo; Morie A Gertz; Philip R Greipp; Brian Durie; Bart Barlogie; Kenneth C Anderson; William Dalton; Morton Coleman; Susie Novis; Robert A Kyle
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Mayo Clinic proceedings. Mayo Clinic 2010;85(2):197-9; author reply 201-4.
2010: Irene M Ghobrial; Aldo Roccaro; Fangxin Hong; Edie Weller; Nancy Rubin; Renee Leduc; Meghan Rourke; Stacey Chuma; Antonio Sacco; Xiaoying Jia; Feda Azab; Abdel Kareem Azab; Scott Rodig; Diane Warren; Brianna Harris; Lyuba Varticovski; Peter Sportelli; Xavier Leleu; Kenneth C Anderson; Paul G Richardson
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(3):1033-41.
2010: Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen R Chen; Eva Guinan; Georgia B Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010;16(2):157-68.
2010: Dharminder Chauhan; Ajita V Singh; Bryan Ciccarelli; Paul G Richardson; Michael A Palladino; Kenneth C Anderson
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
Blood 2010;115(4):834-45.
2010: Paul G Richardson; Jacob Laubach; Anuj Mahindra; Constantine Mitsiades; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Noopur Raje; Nikhil Munshi; Kenneth C Anderson
The treatment of multiple myeloma patients not eligible for asct.
Mediterranean journal of hematology and infectious diseases 2010;2(2):e2010009.
2009: A Keith Stewart; Paul G Richardson; Jesus F San-Miguel
How I treat multiple myeloma in younger patients.
Blood 2009;114(27):5436-43.
2009: Meletios A Dimopoulos; Paul G Richardson; Rudolf Schlag; Nuriet K Khuageva; Ofer Shpilberg; Efstathios Kastritis; Martin Kropff; Maria T Petrucci; Michel Delforge; Julia Alexeeva; Rik Schots; Tamás Masszi; Maria-Victoria Mateos; William Deraedt; Kevin Liu; Andrew Cakana; Helgi van de Velde; Jesús F San Miguel
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6086-93.
2009: Melissa G Ooi; Patrick J Hayden; Vassiliki Kotoula; Douglas W McMillin; Elpida Charalambous; Emily Daskalaki; Noopur S Raje; Nikhil C Munshi; Dharminder Chauhan; Teru Hideshima; Leutz Buon; Martin Clynes; Peter O'Gorman; Paul G Richardson; Constantine S Mitsiades; Kenneth C Anderson; Nicholas Mitsiades
Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7153-60.
2009: Cinara L Echart; Barbara Graziadio; Simona Somaini; Laura I Ferro; Paul G Richardson; Jawed Fareed; Massimo Iacobelli
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2009;20(8):627-34.
2009: Paul G Richardson; Edie Weller; Sundar Jagannath; David Avigan; Melissa Alsina; Robert Schlossman; Amitabha Mazumder; Nikhil C Munshi; Irene M Ghobrial; Deborah Doss; Diane L Warren; Laura E Lunde; Mary McKenney; Carol Delaney; Constantine S Mitsiades; Teru Hideshima; William Dalton; Robert Knight; Dixie Esseltine; Kenneth C Anderson
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5713-9.
2009: Joseph M Negri; Douglas W McMillin; Jake Delmore; Nicholas Mitsiades; Patrick Hayden; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Carolyn A Buser; John Pollard; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
2009: J P Laubach; A Mahindra; Constantine S Mitsiades; R L Schlossman; Nikhil C Munshi; I M Ghobrial; N Carreau; Teru Hideshima; Kenneth C Anderson; Paul G Richardson
The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Leukemia 2009;23(12):2222-32.
2009: Dan T Vogl; Edward A Stadtmauer; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Thierry Facon; Jean-Luc Harousseau; Anthony Boral; Rachel Neuwirth; Kenneth C Anderson
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
British journal of haematology 2009;147(4):531-4.
2009: Jacob P Laubach; Constantine S Mitsiades; Anuj Mahindra; Robert L Schlossman; Teru Hideshima; Dharminder Chauhan; Nicole A Carreau; Irene M Ghobrial; Noopur Raje; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Novel therapies in the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):947-60.
2009: Jacob P Laubach; Paul G Richardson; Kenneth C Anderson
Hematology: Thalidomide maintenance in multiple myeloma.
Nature reviews. Clinical oncology 2009;6(10):565-6.
2009: Sergio Giralt; E A Stadtmauer; Jean-Luc Harousseau; Antonio Palumbo; W Bensinger; R L Comenzo; S Kumar; N C Munshi; A Dispenzieri; R Kyle; G Merlini; J San Miguel; Heinz Ludwig; R Hajek; Sundar Jagannath; J Blade; Sagar Lonial; M A Dimopoulos; H Einsele; Bart Barlogie; Kenneth C Anderson; M Gertz; M Attal; P Tosi; Pieter Sonneveld; Mario Boccadoro; G Morgan; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; Wesley Chen; K Shimizu; R Powles; Paul G Richardson; R Niesvizky; S V Rajkumar; B G M Durie
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Leukemia 2009;23(10):1904-12.
2009: Antonio Palumbo; O Sezer; R Kyle; J S Miguel; Robert Z Orlowski; P Moreau; R Niesvizky; G Morgan; R Comenzo; Pieter Sonneveld; S Kumar; R Hajek; Sergio Giralt; S Bringhen; Kenneth C Anderson; Paul G Richardson; M Cavo; F Davies; J Bladé; H Einsele; M A Dimopoulos; A Spencer; A Dispenzieri; T Reiman; K Shimizu; J H Lee; M Attal; Mario Boccadoro; M Mateos; W Chen; Heinz Ludwig; D Joshua; J Chim; V Hungria; I Turesson; B G M Durie; Sagar Lonial
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
Leukemia 2009;23(10):1716-30.
2009: Shaji Kumar; Sergio Giralt; Edward A Stadtmauer; Jean-Luc Harousseau; Antonio Palumbo; William Bensinger; Raymond Comenzo; Suzanne Lentzsch; Nikhil Munshi; Ruben Niesvizky; Jesús San Miguel; Heinz Ludwig; Leif Bergsagel; Joan Blade; Sagar Lonial; Kenneth C Anderson; Patrizia Tosi; Pieter Sonneveld; Orhan Sezer; David H Vesole; Michele Cavo; Hermann Einsele; Paul G Richardson; Brian G M Durie; S Vincent Rajkumar
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood 2009;114(9):1729-35.
2009: Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; klaus podar; Constantine S Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
2009: Marc S Raab; klaus podar; Iris Breitkreutz; Paul G Richardson; Kenneth C Anderson
Multiple myeloma.
Lancet 2009;374(9686):324-39.
2009: Paul G Richardson; Wanling Xie; Constantine S Mitsiades; Asher A Chanan-Khan; Sagar Lonial; Hani Hassoun; David Avigan; Anne Louise Oaklander; David J Kuter; Patrick Y Wen; Santosh kesari; Hannah R Briemberg; Robert Schlossman; Nikhil C Munshi; L Thompson Heffner; Deborah Doss; Dixie Esseltine; Edie Weller; Kenneth C Anderson; Anthony A Amato
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3518-25.
2009: Douglas W McMillin; Melissa Ooi; Jake Delmore; Joseph Negri; Patrick J Hayden; Nicholas Mitsiades; Jana Jakubikova; Sauveur-Michel Maira; Carlos Garcia-Echeverria; Robert Schlossman; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Cancer research 2009;69(14):5835-42.
2009: Christine Chen; Donna E Reece; David Siegel; Ruben Niesvizky; Ralph V Boccia; Edward A Stadtmauer; Rafat Abonour; Paul G Richardson; Jeffrey Matous; Shaji Kumar; Nizar J Bahlis; Melissa Alsina; Robert Vescio; Steven E Coutre; Dennis Pietronigro; Robert D Knight; Jerome B Zeldis; Vincent Rajkumar
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
British journal of haematology 2009;146(2):164-70.
2009: Hiroshi Ikeda; Teru Hideshima; Mariateresa Fulciniti; Robert J Lutz; Hiroshi Yasui; Yutaka Okawa; Tanyel Kiziltepe; Sonia Vallet; Samantha Pozzi; Loredana Santo; Giulia Perrone; Yu-Tzu Tai; Diana Cirstea; Noopur S Raje; Christoph Uherek; Benjamin Dälken; Silke Aigner; Frank Osterroth; Nikhil Munshi; Paul G Richardson; Kenneth C Anderson
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4028-37.
2009: Teru Hideshima; Dharminder Chauhan; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Okawa; klaus podar; Noopur Raje; Alexei Protopopov; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
Blood 2009;113(21):5228-36.
2009: Jacob P Laubach; Constantine S Mitsiades; Aldo Roccaro; Irene M Ghobrial; Kenneth C Anderson; Paul G Richardson
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
Leukemia & lymphoma 2009;50(5):694-702.
2009: N Raje; T Hideshima; S Mukherjee; M Raab; S Vallet; S Chhetri; D Cirstea; S Pozzi; C Mitsiades; M Rooney; T Kiziltepe; K Podar; Y Okawa; H Ikeda; R Carrasco; Paul G Richardson; D Chauhan; N C Munshi; S Sharma; H Parikh; B Chabner; D Scadden; Kenneth C Anderson
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Leukemia 2009;23(5):961-70.
2009: Jacob Laubach; Constantine Mitsiades; Kenneth C Anderson; Paul G Richardson
Maximizing the clinical benefit of novel therapies in multiple myeloma.
Oncology (Williston Park, N.Y.) 2009;23(5):415-6, 419.
2009: Constantine S Mitsiades; Teru Hideshima; Dharminder Chauhan; Douglas W McMillin; Steffen Klippel; Jacob P Laubach; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
2009: klaus podar; Yu-Tzu Tai; Teru Hideshima; Sonia Vallet; Paul G Richardson; Kenneth C Anderson
Emerging therapies for multiple myeloma.
Expert opinion on emerging drugs 2009;14(1):99-127.
2009: Hani Mawardi; Nathaniel Treister; Paul G Richardson; Kenneth C Anderson; Nikhil Munshi; Robert A Faiella; Sook-Bin Woo
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2009;67(3):593-601.
2009: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Anthony Boral; Dixie Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
2009: Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1210-21.
2009: A Dispenzieri; R Kyle; G Merlini; J S Miguel; Heinz Ludwig; R Hajek; Antonio Palumbo; Sundar Jagannath; J Blade; Sagar Lonial; M Dimopoulos; R Comenzo; H Einsele; Bart Barlogie; Kenneth C Anderson; M Gertz; Jean-Luc Harousseau; M Attal; P Tosi; Pieter Sonneveld; Mario Boccadoro; G Morgan; Paul G Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Leukemia 2009;23(2):215-24.
2009: Paul G Richardson; J San-Miguel; Sagar Lonial; D Reece; Andrzej J Jakubowiak; M Hussein; Sundar Jagannath; C S Mitsiades; N Raje; J Kaufman; D Avigan; I Ghobrial; R L Schlossman; N Munshi; W Dalton; Kenneth C Anderson
The research mission in myeloma.
Leukemia 2009;23(2):422-3; author reply 423-4.
2009: Jacob P Laubach; Constantine S Mitsiades; Teru Hideshima; Robert Schlossman; Dharminder Chauhan; Nikhil Munshi; Irene Ghobrial; Nicole Carreau; Kenneth C Anderson; Paul G Richardson
Bortezomib in the management of multiple myeloma.
Cancer management and research 2009;1():107-17.
2008: Stephanie J Lee; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Jesús F San Miguel; Bruce Crawford; Joseph Massaro; Ravinder Dhawan; Sanjay Gupta; Kenneth C Anderson
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
British journal of haematology 2008;143(4):511-9.
2008: Sundar Jagannath; Bart Barlogie; James R Berenson; David S Siegel; David Irwin; Paul G Richardson; Ruben Niesvizky; Raymond Alexanian; Steven A Limentani; Melissa Alsina; Dixie Esseltine; Kenneth C Anderson
Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
British journal of haematology 2008;143(4):537-40.
2008: Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4784-90.
2008: Jeffrey Wolf; Paul G Richardson; Michael Schuster; Annette LeBlanc; Ian B Walters; David S Battleman
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Clinical advances in hematology & oncology : H&O 2008;6(10):755-60.
2008: Sagar Lonial; Paul G Richardson; Jesús San Miguel; Pieter Sonneveld; Michael W Schuster; Joan Bladé; Jamie Cavenagh; S Vincent Rajkumar; Andrzej J Jakubowiak; Dixie Esseltine; Kenneth C Anderson; Jean-Luc Harousseau
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
2008: Ruben Niesvizky; Paul G Richardson; S Vincent Rajkumar; Morton Coleman; Laura Rosiñol; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Anthony L Boral; Dixie Esseltine; Kenneth C Anderson; Joan Bladé
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
British journal of haematology 2008;143(1):46-53.
2008: I Breitkreutz; M S Raab; S Vallet; T Hideshima; N Raje; C Mitsiades; D Chauhan; Y Okawa; N C Munshi; Paul G Richardson; Kenneth C Anderson
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Leukemia 2008;22(10):1925-32.
2008: Aldo Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
Biologics : targets & therapy 2008;2(3):419-31.
2008: Jesús F San Miguel; Rudolf Schlag; Nuriet K Khuageva; Meletios A Dimopoulos; Ofer Shpilberg; Martin Kropff; Ivan Spicka; Maria T Petrucci; Antonio Palumbo; Olga S Samoilova; Anna Dmoszynska; Kudrat M Abdulkadyrov; Rik Schots; Bin Jiang; Maria-Victoria Mateos; Kenneth C Anderson; Dixie Esseltine; Kevin Liu; Andrew Cakana; Helgi van de Velde; Paul G Richardson
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
The New England journal of medicine 2008;359(9):906-17.
2008: Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter C Burger; Alfred I Lee; klaus podar; Teru Hideshima; Audie G Rice; A van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul G Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood 2008;112(4):1329-37.
2008: Constantine S Mitsiades; Enrique M Ocio; Atanasio Pandiella; Patricia Maiso; Consuelo Gajate; Mercedes Garayoa; David Vilanova; Juan Carlos Montero; Nicholas Mitsiades; Ciaran J McMullan; Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Pablo Aviles; Gabriel Otero; Glynn Faircloth; M Victoria Mateos; Paul G Richardson; Faustino Mollinedo; Jesus F San-Miguel; Kenneth C Anderson
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
2008: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
2008: Nikhil C Munshi; Constantine S Mitsiades; Paul G Richardson; Kenneth C Anderson
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
Nature clinical practice. Oncology 2008;5(7):374-5.
2008: Nathaniel S Treister; Paul G Richardson; Robert Schlossman; Kenneth Miller; Sook-Bin Woo
Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2008;105(6):e1-4.
2008: Yutaka Okawa; Teru Hideshima; Hiroshi Ikeda; Noopur Raje; Sonia Vallet; Tanyel Kiziltepe; Hiroshi Yasui; Sotaro Enatsu; Samantha Pozzi; Iris Breitkreutz; Diana Cirstea; Loredana Santo; Paul G Richardson; Kenneth C Anderson
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
British journal of haematology 2008;141(5):659-71.
2008: Noopur Raje; Sook-Bin Woo; Karen Hande; Jeff T Yap; Paul G Richardson; Sonia Vallet; Nathaniel S Treister; Teru Hideshima; Niall Sheehy; Shweta Chhetri; Brendan Connell; Wanling Xie; Yu-Tzu Tai; Agnieszka Szot-Barnes; Mei Tian; Robert Schlossman; Edie Weller; Nikhil C Munshi; Annick D Van den Abbeele; Kenneth C Anderson
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2387-95.
2008: Jesús F San Miguel; Paul G Richardson; Pieter Sonneveld; M W Schuster; David Irwin; E A Stadtmauer; T Facon; Jean-Luc Harousseau; D Ben-Yehuda; Sagar Lonial; H Goldschmidt; D Reece; Joan Bladé; Mario Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; Dixie Esseltine; Kenneth C Anderson
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Leukemia 2008;22(4):842-9.
2008: Paul G Richardson; Ruben Niesvizky; Kenneth C Anderson; Joan Bladé
Re: When you look matters: the effect of assessment schedule on progression-free survival.
Journal of the National Cancer Institute 2008;100(5):373.
2008: Teru Hideshima; Noopur Raje; Paul G Richardson; Kenneth C Anderson
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Therapeutics and clinical risk management 2008;4(1):129-36.
2008: Paul G Richardson
The myeloma landscape in 2008.
Clinical advances in hematology & oncology : H&O 2008;6(2 Suppl 2):1-12; quiz 15-6.
2008: Alissa Huston; Xavier Leleu; Xiaoying Jia; Anne-Sophie Moreau; Hai T Ngo; Judith Runnels; Judy Anderson; Yazan Alsayed; Aldo Roccaro; Sonia Vallet; Evdoxia Hatjiharissi; Yu-Tzu Tai; Peter Sportelli; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; David G Roodman; Kenneth C Anderson; Irene M Ghobrial
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):865-74.
2008: Antonio Palumbo; S V Rajkumar; M A Dimopoulos; Paul G Richardson; J San Miguel; Bart Barlogie; Jean-Luc Harousseau; Jeffrey A Zonder; M Cavo; M Zangari; M Attal; A Belch; S Knop; D Joshua; O Sezer; Heinz Ludwig; D Vesole; J Bladé; R Kyle; J Westin; D Weber; S Bringhen; R Niesvizky; A Waage; M von Lilienfeld-Toal; Sagar Lonial; G J Morgan; Robert Z Orlowski; K Shimizu; Kenneth C Anderson; Mario Boccadoro; B G Durie; Pieter Sonneveld; M A Hussein
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia 2008;22(2):414-23.
2008: Vincent T Ho; C Revta; Paul G Richardson
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Bone marrow transplantation 2008;41(3):229-37.
2007: Constantine S Mitsiades; Patrick J Hayden; Kenneth C Anderson; Paul G Richardson
From the bench to the bedside: emerging new treatments in multiple myeloma.
Best practice & research. Clinical haematology 2007;20(4):797-816.
2007: klaus podar; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
The malignant clone and the bone-marrow environment.
Best practice & research. Clinical haematology 2007;20(4):597-612.
2007: Efstathios Kastritis; Constantine S Mitsiades; Meletios A Dimopoulos; Paul G Richardson
Management of relapsed and relapsed refractory myeloma.
Hematology/oncology clinics of North America 2007;21(6):1175-215, x.
2007: Constantine S Mitsiades; Douglas W McMillin; Steffen Klippel; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
2007: Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej J Jakubowiak; William Dalton; Anthony Boral; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
2007: Patrick J Hayden; Constantine S Mitsiades; Kenneth C Anderson; Paul G Richardson
Novel therapies in myeloma.
Current opinion in hematology 2007;14(6):609-15.
2007: A Keith Stewart; Hong Chang; Suzanne Trudel; Kenneth C Anderson; Paul G Richardson; M Alsina; Donna Reece; S Young; A Sable-Hunt; Z Li; Jonathan J Keats; Scott A Van Wier; Gregory J Ahmann; Tammy Price-Troska; K Giusti; P Leif Bergsagel; Marta Chesi; Rafael Fonseca
Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.
Leukemia 2007;21(11):2358-9.
2007: S Vincent Rajkumar; Paul G Richardson; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Thomas E Witzig; Robert Schlossman; Carolyn F Sidor; Kenneth C Anderson; Morie A Gertz
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6162-7.
2007: Iris Breitkreutz; Marc S Raab; Sonia Vallet; Teru Hideshima; Noopur Raje; Dharminder Chauhan; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
British journal of haematology 2007;139(1):55-63.
2007: Teru Hideshima; Laurence Catley; Noopur Raje; Dharminder Chauhan; klaus podar; Constantine S Mitsiades; Yu-Tzu Tai; Sonia Vallet; Tanyel Kiziltepe; Enrique M Ocio; Hiroshi Ikeda; Yutaka Okawa; Hiromasa Hideshima; Nikhil C Munshi; Hiroshi Yasui; Paul G Richardson; Kenneth C Anderson
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
2007: Maurizio Zangari; Dixie Esseltine; Federica Cavallo; Rachel Neuwirth; Francesca Elice; Michael J Burns; Shmuel Yaccoby; Paul G Richardson; Pieter Sonneveld; Guido Tricot
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
American journal of hematology 2007;82(9):831-3.
2007: Teru Hideshima; Constantine S Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
2007: Constantine S Mitsiades; Nicholas Mitsiades; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
Journal of cellular biochemistry 2007;101(4):950-68.
2007: Nikhil C Munshi; Constantine S Mitsiades; Paul G Richardson; Kenneth C Anderson
Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
Nature clinical practice. Oncology 2007;4(7):394-5.
2007: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Nikhil C Munshi; Kenneth C Anderson
New drugs for myeloma.
The oncologist 2007;12(6):664-89.
2007: Vincent T Ho; Erica Linden; Carolyn Revta; Paul G Richardson
Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
Seminars in thrombosis and hemostasis 2007;33(4):373-88.
2007: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Jesús F San Miguel; Jamie Cavenagh; Kenneth C Anderson
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
British journal of haematology 2007;137(5):429-35.
2007: George Mulligan; Constantine S Mitsiades; Bryant Barbara; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul G Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David P Schenkein; Dixie Esseltine; Anthony Boral; Kenneth C Anderson
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
2007: klaus podar; Paul G Richardson; Dharminder Chauhan; Kenneth C Anderson
Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Expert review of anticancer therapy 2007;7(4):551-66.
2007: Asher Chanan-Khan; Jonathan L Kaufman; Jayesh Mehta; Paul G Richardson; Kena C Miller; Sagar Lonial; Nikhil C Munshi; Robert Schlossman; Joseph Tariman; Seema Singhal
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
Blood 2007;109(6):2604-6.
2007: Hiroshi Yasui; Teru Hideshima; H Ikeda; Enrique M Ocio; Tanyel Kiziltepe; Sonia Vallet; Y Okawa; Paola Neri; Kumar Sukhdeo; klaus podar; Dharminder Chauhan; Paul G Richardson; Noopur Raje; Daniel R Carrasco; Kenneth C Anderson
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia 2007;21(3):535-40.
2007: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
2007: John Koreth; Corey Cutler; Benjamin Djulbegovic; Rajesh Behl; Robert Schlossman; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson; Robert J Soiffer; Edwin P Alyea
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2007;13(2):183-96.
2007: Hiroshi Yasui; Teru Hideshima; Hiroshi Ikeda; Janice Jin; Enrique M Ocio; Tanyel Kiziltepe; Yutaka Okawa; Sonia Vallet; klaus podar; Kenji Ishitsuka; Paul G Richardson; Christopher A Pargellis; Neil Moss; Noopur Raje; Kenneth C Anderson
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
British journal of haematology 2007;136(3):414-23.
2007: Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):247-56.
2007: Paul G Richardson; Constantine S Mitsiades; Robert Schlossman; Irene M Ghobrial; Teru Hideshima; Dharminder Chauhan; Nikhil C Munshi; Kenneth C Anderson
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
2007: Sundar Jagannath; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; J M Cowan; Kenneth C Anderson
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia 2007;21(1):151-7.
2006: Aldo Roccaro; T Hideshima; Paul G Richardson; D Russo; Dragana Vukasovic; Angelo Vacca; Franco Dammacco; Kenneth C Anderson
Bortezomib as an antitumor agent.
Current pharmaceutical biotechnology 2006;7(6):441-8.
2006: Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome B Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
2006: Orhan Sezer; David H Vesole; Seema Singhal; Paul G Richardson; Edward A Stadtmauer; Christian Jakob; Anthony Boral; Dixie Esseltine; Jayesh Mehta
Bortezomib-induced tumor lysis syndrome in multiple myeloma.
Clinical lymphoma & myeloma 2006;7(3):233-5.
2006: Paul G Richardson; Constantine S Mitsiades; Nikhil C Munshi; Kenneth C Anderson
Can thalidomide improve outcome in patients with multiple myeloma?
Nature clinical practice. Oncology 2006;3(11):590-1.
2006: Paul G Richardson; Constantine S Mitsiades; Irene M Ghobrial; Kenneth C Anderson
Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
Current opinion in oncology 2006;18(6):598-608.
2006: Hiroshi Yasui; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Recent advances in the treatment of Multiple Myeloma.
Current pharmaceutical biotechnology 2006;7(5):381-93.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
2006: B G M Durie; Jean-Luc Harousseau; J S Miguel; J Bladé; Bart Barlogie; Kenneth C Anderson; M Gertz; M Dimopoulos; J Westin; Pieter Sonneveld; Heinz Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; Guido Tricot; M Attal; G Merlini; R Powles; Paul G Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
International uniform response criteria for multiple myeloma.
Leukemia 2006;20(9):1467-73.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
2006: Sundar Jagannath; Paul G Richardson; Bart Barlogie; James R Berenson; shashank singhal; David Irwin; Gordan Srkalovic; David P Schenkein; Dixie Esseltine; Kenneth C Anderson
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
Haematologica 2006;91(7):929-34.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
European journal of cancer (Oxford, England : 1990) 2006;42(11):1564-73.
2006: Paul G Richardson; Hannah R Briemberg; Sundar Jagannath; Patrick Y Wen; Bart Barlogie; James Berenson; shashank singhal; David S Siegel; David Irwin; Michael Schuster; Gordan Srkalovic; Raymond Alexanian; S Vincent Rajkumar; Steven A Limentani; Melissa Alsina; Robert Z Orlowski; Kevin Najarian; Dixie Esseltine; Kenneth C Anderson; Anthony A Amato
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3113-20.
2006: Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
2006: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Kenneth C Anderson
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
Cancer 2006;106(6):1316-9.
2006: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Current therapeutic uses of lenalidomide in multiple myeloma.
Expert opinion on investigational drugs 2006;15(2):171-9.
2006: Hiroshi Yasui; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
British journal of haematology 2006;132(4):385-97.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Andrew L Kung; Faith E Davies; Gareth Morgan; Masaharu Akiyama; Reshma Shringarpure; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Neal Rosen; Kenneth C Anderson
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2006: Paul G Richardson; Kenneth C Anderson
Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):334-6.
2006: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
2006: Aldo Roccaro; Teru Hideshima; Noopur Raje; Shaji Kumar; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Dragana Vukasovic; Beatrice Nico; Angelo Vacca; Franco Dammacco; Paul G Richardson; Kenneth C Anderson
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Cancer research 2006;66(1):184-91.
2005: Paul G Richardson; Robert Schlossman; Teru Hideshima; Kenneth C Anderson
New treatments for multiple myeloma.
Oncology (Williston Park, N.Y.) 2005;19(14):1781-92; discussion 1792, 1795-7.
2005: Margaret O Little; Walter V Moczynski; Paul G Richardson; Steven Joffe
Dana-Farber Cancer Institute ethics rounds: life-threatening illness and the desire to adopt.
Kennedy Institute of Ethics journal 2005;15(4):385-93.
2005: Sagar Lonial; Edmond WALLER; Paul G Richardson; Sundar Jagannath; Robert Z Orlowski; Cynthia R Giver; David L Jaye; Dixil Francis; Sara Giusti; Claire Torre; Bart Barlogie; James R Berenson; Seema Singhal; David P Schenkein; Dixie Esseltine; Jessica Anderson; Hugh Xiao; Leonard T Heffner; Kenneth C Anderson
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood 2005;106(12):3777-84.
2005: James R Berenson; Sundar Jagannath; Bart Barlogie; David T Siegel; Raymond Alexanian; Paul G Richardson; David Irwin; Melissa Alsina; S Vincent Rajkumar; Gordan Srkalovic; shashank singhal; Steven A Limentani; Ruben Niesvizky; Dixie Esseltine; Elizabeth Trehu; David P Schenkein; Kenneth C Anderson
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
Cancer 2005;104(10):2141-8.
2005: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Teru Hideshima; Hugh Xiao; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
2005: Maurizio Zangari; Dixie Esseltine; Choon-Kee Lee; Bart Barlogie; Francesca Elice; Michael J Burns; Seung-Hee Kang; Shmuel Yaccoby; Kevin Najarian; Paul G Richardson; Pieter Sonneveld; Guido Tricot
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
British journal of haematology 2005;131(1):71-3.
2005: Paul G Richardson; Robert Schlossman; Constantine S Mitsiades; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
2005: Hiroshi Yasui; Teru Hideshima; Noopur Raje; Aldo Roccaro; Norihiko Shiraishi; Shaji Kumar; Makoto Hamasaki; Kenji Ishitsuka; Yu-Tzu Tai; klaus podar; Laurence Catley; Constantine S Mitsiades; Paul G Richardson; Rainer Albert; Volker Brinkmann; Dharminder Chauhan; Kenneth C Anderson
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
2005: Sook-Bin Woo; Karen Hande; Paul G Richardson
Osteonecrosis of the jaw and bisphosphonates.
The New England journal of medicine 2005;353(1):99-102; discussion 99-102.
2005: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesús F San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony Boral; Dixie Esseltine; Jane B Porter; David P Schenkein; Kenneth C Anderson
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
2005: John G Gribben; David P Ryan; Richard N. Boyajian; Robert G Urban; Mary Lynne Hedley; Kathleen Beach; Patrick Nealon; Ursula Matulonis; Susana Campos; Timothy D Gilligan; Paul G Richardson; Blossom Marshall; Donna Neuberg; Lee M Nadler
Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4430-6.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
2005: Makoto Hamasaki; Teru Hideshima; Pierfrancesco Tassone; Paola Neri; Kenji Ishitsuka; Hiroshi Yasui; Norihiko Shiraishi; Noopur Raje; Shaji Kumar; Donald Picker; Gary S Jacob; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood 2005;105(11):4470-6.
2005: Scott R Floyd; Liron Pantanowitz; David F McDermott; Jennifer Yannucci; Jane A Driver; Mary Ann Stevenson; Benjamin David Smith; Lynn D Wilson; Paul G Richardson
Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):3138-40.
2005: Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Hiroshi Yasui; Noopur Raje; Shaji Kumar; klaus podar; Constantine S Mitsiades; Hiromasa Hideshima; Lynn Bonham; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
2005: Paul G Richardson; Constantine S Mitsiades
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Future oncology (London, England) 2005;1(2):161-71.
2005: William P Peters; Gary Rosner; James J Vredenburgh; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Lawrence Marks; Constance Cirrincione; Larry Norton; I Craig Henderson; Richard L Schilsky; David D Hurd
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2191-200.
2005: Sundar Jagannath; Bart Barlogie; James R Berenson; shashank singhal; Raymond Alexanian; Gordan Srkalovic; Robert Z Orlowski; Paul G Richardson; Jessica Anderson; Darrell Nix; Dixie Esseltine; Kenneth C Anderson
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Cancer 2005;103(6):1195-200.
2005: Abie Craiu; Yoriko Saito; Ana Limon; Henry M Eppich; Douglas P Olson; Neil Rodrigues; Gregor B Adams; David Dombkowski; Paul G Richardson; Robert Schlossman; Peter S Choi; Jonathan Grogins; Paula G O'Connor; Kenneth Cohen; Eyal C Attar; Jay Freshman; Rebecca Rich; Joseph A Mangano; John G Gribben; Kenneth C Anderson; David T Scadden
Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
Blood 2005;105(5):2235-8.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
2005: S Vincent Rajkumar; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Proteasome inhibition as a novel therapeutic target in human cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):630-9.
2005: Constantine S Mitsiades; Nicholas Mitsiades; Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
2005: Paul G Richardson; Constantine S Mitsiades; Teru Hideshima; Kenneth C Anderson
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
2005: Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; klaus podar; Hiroshi Yasui; Noopur Raje; Shaji Kumar; Dharminder Chauhan; Steve P Treon; Paul G Richardson; Kenneth C Anderson
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
British journal of haematology 2005;128(2):192-203.
2005: Stephanie J Lee; Fausto R Loberiza; Joseph H Antin; T Kirkpatrick; L Prokop; Edwin P Alyea; Corey Cutler; Vincent T Ho; Paul G Richardson; Robert Schlossman; David C Fisher; B Logan; Robert J Soiffer
Routine screening for psychosocial distress following hematopoietic stem cell transplantation.
Bone marrow transplantation 2005;35(1):77-83.
2004: Paul G Richardson; Ara Kassarjian; Wen Jing
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 38-2004. A 40-year-old man with a large tumor of the skull.
The New England journal of medicine 2004;351(25):2637-45.
2004: Teru Hideshima; klaus podar; Dharminder Chauhan; Kenji Ishitsuka; Constantine S Mitsiades; Yu-Tzu Tai; Makoto Hamasaki; Noopur Raje; Hiromasa Hideshima; George F Schreiner; Aaron N Nguyen; Tony A Navas; Nikhil C Munshi; Paul G Richardson; Linda S Higgins; Kenneth C Anderson
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
2004: Steven Le Gouill; klaus podar; Martine Amiot; Teru Hideshima; Dharminder Chauhan; Kenji Ishitsuka; Shaji Kumar; Noopur Raje; Paul G Richardson; Jean-Luc Harousseau; Kenneth C Anderson
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
2004: klaus podar; Reshma Shringarpure; Yu-Tzu Tai; Melissa Simoncini; Martin Sattler; Kenji Ishitsuka; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer research 2004;64(20):7500-6.
2004: Sundar Jagannath; Bart Barlogie; James Berenson; David Siegel; David Irwin; Paul G Richardson; Ruben Niesvizky; Raymond Alexanian; Steven A Limentani; Melissa Alsina; Julian Adams; M Kauffman; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
British journal of haematology 2004;127(2):165-72.
2004: Paul G Richardson; Kenneth C Anderson
Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(16):3212-4.
2004: Vincent T Ho; Parisa Momtaz; Colleen Didas; Martha Wadleigh; Paul G Richardson
Post-transplant hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
Reviews in clinical and experimental hematology 2004;8(1):E3.
2004: Paul G Richardson
A review of the proteasome inhibitor bortezomib in multiple myeloma.
Expert opinion on pharmacotherapy 2004;5(6):1321-31.
2004: klaus podar; Laurence Catley; Yu-Tzu Tai; Reshma Shringarpure; Pedro Carvalho; Toshiaki Hayashi; Renate Burger; Robert Schlossman; Paul G Richardson; Lini Pandite; Rakesh Kumar; Teru Hideshima; Dharminder Chauhan; Kenneth C Anderson
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Blood 2004;103(9):3474-9.
2004: Richard LeBlanc; Teru Hideshima; Laurence Catley; Reshma Shringarpure; Renate Burger; Nicholas Mitsiades; Constantine S Mitsiades; Puneet Cheema; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson; Nikhil C Munshi
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
2004: Jean-Luc Harousseau; John Shaughnessy; Paul G Richardson
Multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2004;():237-56.
2004: Paul G Richardson; Teru Hideshima; Constantine S Mitsiades; Kenneth C Anderson
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; klaus podar; Masaharu Akiyama; Constantine S Mitsiades; Nicholas Mitsiades; Baoqing Gong; Lynn Bonham; Peter de Vries; Nikhil C Munshi; Paul G Richardson; Jack W Singer; Kenneth C Anderson
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
2003: Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Masaharu Akiyama; Nicholas Mitsiades; Constantine S Mitsiades; klaus podar; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
2003: Martha Wadleigh; Vincent T Ho; Parisa Momtaz; Paul G Richardson
Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment.
Current opinion in hematology 2003;10(6):451-62.
2003: Paul G Richardson; Kenneth C Anderson
Bortezomib: a novel therapy approved for multiple myeloma.
Clinical advances in hematology & oncology : H&O 2003;1(10):596-600.
2003: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Cancer control : journal of the Moffitt Cancer Center 2003;10(5):361-9.
2003: Martha Wadleigh; Paul G Richardson; David Zahrieh; Stephanie J Lee; Corey Cutler; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Richard M Stone; Robert J Soiffer; Daniel J DeAngelo
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Blood 2003;102(5):1578-82.
2003: Paul G Richardson; Bart Barlogie; James Berenson; shashank singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
2003: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Targeting proteasome inhibition in hematologic malignancies.
Reviews in clinical and experimental hematology 2003;7(2):191-204.
2003: Britta Maecker; Karen S Anderson; Michael S von Bergwelt-Baildon; Edie Weller; Robert H Vonderheide; Paul G Richardson; Robert Schlossman; Isaura A Menezes; Zhinan Xia; Nikhil C Munshi; Kenneth C Anderson; Lee M Nadler; Joachim L Schultze
Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.
British journal of haematology 2003;121(6):842-8.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Ciaran McMullan; Vassiliki Poulaki; Galinos Fanourakis; Robert Schlossman; Dharminder Chauhan; Nikhil C Munshi; Teru Hideshima; Victoria M Richon; Paul A Marks; Kenneth C Anderson
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
2003: Constantine S Mitsiades; Nicholas Mitsiades; Paul G Richardson; Steve P Treon; Kenneth C Anderson
Novel biologically based therapies for Waldenstrom's macroglobulinemia.
Seminars in oncology 2003;30(2):309-12.
2003: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
2002: Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert J Soiffer; Thomas R Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James J Vredenburgh; Allen R Chen; Sally Arai; Georgia B Vogelsang; George B McDonald; Eva C Guinan
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Blood 2002;100(13):4337-43.
2002: Paul G Richardson; Robert Schlossman; Edie Weller; Teru Hideshima; Constantine S Mitsiades; Faith Davies; Richard LeBlanc; Laurence Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome B Zeldis; Kenneth C Anderson
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
2002: Boris Lin; klaus podar; Deepak Gupta; Yu-Tzu Tai; Sigui Li; Edie Weller; Teru Hideshima; Suzanne Lentzsch; Faith Davies; Cheng Li; Ellen Weisberg; Robert Schlossman; Paul G Richardson; James D Griffin; Jeanette Wood; Nikhil C Munshi; Kenneth C Anderson
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
2002: Richard LeBlanc; Laurence Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
2002: Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steve P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
2002: Nikhil C Munshi; Teru Hideshima; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Novel biologically based therapies for multiple myeloma.
International journal of hematology 2002;76 Suppl 1():340-1.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
2002: Nicholas Mitsiades; Constantine S Mitsiades; Vassiliki Poulaki; Dharminder Chauhan; Paul G Richardson; Teru Hideshima; Nikhil C Munshi; Steve P Treon; Kenneth C Anderson
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
2002: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Thalidomide in multiple myeloma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(3):115-28.
2002: Paul G Richardson; Teru Hideshima; Kenneth C Anderson
Thalidomide: emerging role in cancer medicine.
Annual review of medicine 2002;53():629-57.
2001: Paul G Richardson
Basilar artery thrombosis.
Emergency medicine (Fremantle, W.A.) 2001;13(3):367-72.
2001: Faith E Davies; Noopur Raje; Teru Hideshima; Suzanne Lentzsch; Gloria Young; Yu-Tzu Tai; Boris Lin; klaus podar; Deepak Gupta; Dharminder Chauhan; Steve P Treon; Paul G Richardson; Robert Schlossman; G J Morgan; George W Muller; David I Stirling; Kenneth C Anderson
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood 2001;98(1):210-6.
2001: Harold J Burstein; Irene Kuter; Susana Campos; Rebecca Gelman; L Tribou; Leroy M Parker; Judith Manola; Jerry Younger; Ursula Matulonis; Craig A Bunnell; Ann H Partridge; Paul G Richardson; K Clarke; Larry N Shulman; Eric P Winer
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2722-30.
1998: Paul G Richardson; Anthony D Elias; A Krishnan; C Wheeler; R Nath; D Hoppensteadt; N M Kinchla; Donna Neuberg; Edmond WALLER; Joseph H Antin; Robert J Soiffer; James J Vredenburgh; M Lill; A E Woolfrey; Scott I Bearman; M Iacobelli; J Fareed; Eva C Guinan
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Blood 1998;92(3):737-44.
1992: Paul G Richardson; M J Millward; J J Shrimankar; B M Cantwell
Metastatic melanoma to the testis simulating primary seminoma.
British journal of urology 1992;69(6):663-5.
1991: B M Cantwell; Paul G Richardson; S J Campbell
Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men.
Postgraduate medical journal 1991;67(789):675-7.